Table 3.
Pharmacokinetic Measures by HIV Status, Nutritional Status, and Administration Method of Moxifloxacin in Children (n = 23)
| Characteristic | Cmax, µg/mL |
Tmax, h |
AUC0–8, µg × h/mL |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No. | Median (IQR) | P Value | No. | Median (Range) | P Value | No. | Median (IQR) | P Value | |
| HIV-status | |||||||||
| HIV-infected | 6 | 2.83 (2.36–2.94) | 6 | 2.0 (1.0–4.0) | 6 | 13.19 (11.89–15.90) | |||
| HIV-uninfected | 17 | 3.21 (2.95–3.82) | .080 | 17 | 4.0 (1.0–8.0) | .334 | 17 | 19.98 (16.71–25.21) | .003 |
| WAZ | |||||||||
| ≥ − 2.0 | 20 | 3.08 (2.87–3.71) | 20 | 2.0 (1.0–8.0) | 20 | 18.76 (16.43–23.60) | |||
| < − 2.0 (UWA) | 3 | 2.78 (1.99–4.06) | .411 | 3 | 2.0 (1.0–4.0) | .594 | 3 | 14.47 (9.95–15.90) | .045 |
| Administration | |||||||||
| Whole | 20 | 2.96 (2.82–3.71) | 20 | 3.0 (1.0–8.0) | 20 | 17.36 (14.93–23.60) | |||
| Crushed | 3 | 3.21 (3.08–4.06) | .294 | 3 | 1.0 (1.0–2.0) | .047 | 3 | 17.24 (14.47–19.53) | .715 |
Abbreviations: AUC0–8, area under the curve from 0–8 hours; Cmax, maximum serum concentration; HIV, human immunodeficiency virus; IQR, interquartile range; Tmax, time until Cmax; UWA, underweight for age; WAZ, weight-for-age z score.